DnB Asset Management AS Has $327,000 Stock Holdings in Geron Co. (NASDAQ:GERN)

DnB Asset Management AS grew its holdings in Geron Co. (NASDAQ:GERN) by 17.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 92,243 shares of the biopharmaceutical company’s stock after purchasing an additional 13,594 shares during the period. DnB Asset Management AS’s holdings in Geron were worth $327,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. SBI Securities Co. Ltd. acquired a new position in Geron during the 4th quarter worth approximately $28,000. Readystate Asset Management LP bought a new stake in shares of Geron during the third quarter worth $58,000. Rovin Capital UT ADV increased its holdings in shares of Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares in the last quarter. Monterey Private Wealth Inc. bought a new position in shares of Geron in the 4th quarter valued at $63,000. Finally, Paces Ferry Wealth Advisors LLC acquired a new stake in shares of Geron during the 4th quarter valued at $83,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Trading Up 7.4 %

NASDAQ GERN opened at $1.59 on Thursday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.01 billion, a P/E ratio of -4.97 and a beta of 0.54. The business has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $3.32. Geron Co. has a 12 month low of $1.45 and a 12 month high of $5.34.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. On average, analysts predict that Geron Co. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Barclays reiterated an “overweight” rating and issued a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and dropped their price target for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Scotiabank reduced their price objective on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research note on Thursday, February 27th. Stifel Nicolaus lowered their target price on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and an average price target of $5.75.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.